Microbiota and immuno-oncology—a new alliance Mikrobiom und Immuntherapien bei Tumorerkrankungen
Holler E, Weber D, Heudobler D, Wolff D, Herr W (2019)
Publication Type: Journal article
Publication year: 2019
Journal
Book Volume: 14
Pages Range: 426-432
Journal Issue: 10
DOI: 10.1007/s11654-019-00176-5
Abstract
Background: In the last 5 years, the intestinal microbiome has been described as a major driver and modulator of intestinal but also systemic immunoregulation. Materials and methods: Based on the literature and our own experience, we summarize the current knowledge of the role of the microbiome in various types of immunotherapy for the treatment of hematological and solid malignancies. Results and conclusions: Immunological side effects of allogeneic stem cell transplantation but also treatment of solid cancers with checkpoint inhibitors are strongly controlled by intestinal microbiota. Furthermore, recent evidence indicates the contribution of intact microbiota and microbiota-dependent immunoregulation to efficacy and control of tumor growth by checkpoint inhibitors and cellular immunotherapy. Further research addressing microbiota strain-specific mechanisms and metabolites is needed to utilize these interactions for optimization of immunotherapy of cancer.
Involved external institutions
Germany (DE)How to cite
APA:
Holler, E., Weber, D., Heudobler, D., Wolff, D., & Herr, W. (2019). Microbiota and immuno-oncology—a new alliance Mikrobiom und Immuntherapien bei Tumorerkrankungen. Best Practice Onkologie, 14(10), 426-432. https://doi.org/10.1007/s11654-019-00176-5
MLA:
Holler, E., et al. "Microbiota and immuno-oncology—a new alliance Mikrobiom und Immuntherapien bei Tumorerkrankungen." Best Practice Onkologie 14.10 (2019): 426-432.
BibTeX: Download